One question that many biotechs ask when it comes time to partner is:  How does one choose between having a monogamous relationship with one partner on a broad platform vs. doing single-asset deals with multiple partners?

Come join us to hear our panel of local BD experts who will weigh on this topic from both a pharma and venture capital perspective, and discuss various deals that span the spectrum, including:

• The platform deal between Agios and Celgene,
• The staged relationship between Alnylam and Genzyme
• The long engagement between Isis and Biogen
• The R&D externalization model exemplified by the Arteaus and Eli Lilly as part of the Atlas Venture Development Corp initiative.

This is a must-attend event for all BD professionals!